BNP Paribas Financial Markets
ABMD

BNP Paribas Financial Markets’s Abiomed Inc ABMD Stock Holding History

BNP Paribas Financial Markets’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-14,165
Closed -$3.48M – 4925
2022
Q3 		$3.48M Sell
14,165
-3,913
-22% -$1.06M 0.01% 1568
2022
Q2 		$4.47M Buy
18,078
+4,792
+36% +$1.29M 0.01% 1291
2022
Q1 		$4.4M Sell
13,286
-12,240
-48% -$3.77M 0.01% 1370
2021
Q4 		$9.17M Buy
25,526
+9,017
+55% +$3.05M 0.01% 1012
2021
Q3 		$5.37M Sell
16,509
-6,487
-28% -$2.2M 0.01% 1267
2021
Q2 		$7.18M Buy
22,996
+5,222
+29% +$1.6M 0.01% 1119
2021
Q1 		$5.67M Buy
17,774
+14,282
+409% +$4.57M 0.01% 1095
2020
Q4 		$1.13M Sell
3,492
-13,722
-80% -$3.8M ﹤0.01% 1946
2020
Q3 		$4.77M Buy
17,214
+295
+2% +$85K 0.01% 1105
2020
Q2 		$4.09M Sell
16,919
-9,554
-36% -$1.92M 0.01% 1140
2020
Q1 		$3.84M Buy
26,473
+3,734
+16% +$620K 0.01% 1110
2019
Q4 		$3.88M Buy
22,739
+16,467
+263% +$3.05M 0.01% 1332
2019
Q3 		$1.12M Sell
6,272
-24,693
-80% -$5.34M ﹤0.01% 1795
2019
Q2 		$8.07M Sell
30,965
-30,424
-50% -$8.07M 0.02% 821
2019
Q1 		$17.5M Buy
61,389
+47,637
+346% +$15.8M 0.04% 483
2018
Q4 		$4.47M Sell
13,752
-3,566
-21% -$1.24M 0.01% 955
2018
Q3 		$7.79M Buy
17,318
+1,144
+7% +$451K 0.01% 947
2018
Q2 		$6.62M Buy
16,174
+14,017
+650% +$5.08M 0.01% 966
2018
Q1 		$628K Sell
2,157
-6,635
-75% -$1.68M ﹤0.01% 2048
2017
Q4 		$1.65M Sell
8,792
-5,101
-37% -$952K ﹤0.01% 1605
2017
Q3 		$2.34M Sell
13,893
-2,313
-14% -$350K 0.01% 1065
2017
Q2 		$2.32M Buy
16,206
+5,055
+45% +$679K 0.01% 1104
2017
Q1 		$1.4M Sell
11,151
-1,486
-12% -$172K ﹤0.01% 1201
2016
Q4 		$1.42M Buy
12,637
+8,159
+182% +$945K 0.01% 1118
2016
Q3 		$576K Sell
4,478
-11,584
-72% -$1.39M ﹤0.01% 1153
2016
Q2 		$1.76M Buy
16,062
+15,422
+2,410% +$1.53M 0.01% 925
2016
Q1 		$60.7K Sell
640
-7,820
-92% -$660K ﹤0.01% 1945
2015
Q4 		$764K Sell
8,460
-76
-0.9% -$6.45K ﹤0.01% 1193
2015
Q3 		$792K Buy
8,536
+5,064
+146% +$446K ﹤0.01% 1129
2015
Q2 		$228K Buy
3,472
+2,523
+266% +$168K ﹤0.01% 1653
2015
Q1 		$67.9K Buy
+949
New +$51.5K ﹤0.01% 1834
2014
Q4 		– Sell
-2,404
Closed -$59.7K – 3416
2014
Q3 		$59.7K Buy
2,404
+2,316
+2,632% +$58.7K ﹤0.01% 2489
2014
Q2 		$2.21K Buy
+88
New +$2.05K ﹤0.01% 3050
2014
Q1 		– Sell
-502
Closed -$13.4K – 3906
2013
Q4 		$13.4K Sell
502
-10,007
-95% -$247K ﹤0.01% 2461
2013
Q3 		$200K Sell
10,509
-3,045
-22% -$69.6K ﹤0.01% 2264
2013
Q2 		$292K Buy
+13,554
New +$272K ﹤0.01% 2023

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $537M AUM 18.24% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

BNP Paribas Financial Markets's ABMD Position: Q4 2022 in Review

BNP Paribas Financial Markets sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 14,165 shares — an estimated $3.48M sold.

BNP Paribas Financial Markets first reported a position in ABMD in Q2 2013 and held it in 36 quarters. The position peaked at $17.5M in Q1 2019. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • BNP Paribas Financial Markets reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 14,165 Abiomed Inc shares in Q4 2022, an estimated $3.48M.
  • BNP Paribas Financial Markets first reported a position in Abiomed Inc in Q2 2013 and held it in 36 quarters.
  • BNP Paribas Financial Markets's Abiomed Inc position peaked at $17.5M in Q1 2019.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2022, filed 14 Feb 2023.